Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 1:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–10 of 10 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Autonomic Failure, Orthostatic Hypotension
Interventions
Atomoxetine, Acarbose, Pyridostigmine Bromide, Yohimbine, Midodrine HCl, placebo, Modafinil, Octreotide, water intake, Diphenhydramine Hydrochloride, Ranitidine HCL, Tranylcypromine, Ergotamine/ Caffeine, Celecoxib, Pseudoephedrine, Methylphenidate, Indomethacin, Ibuprofen, Oxymetazoline 0.05% nasal solution, Bovril, Acetazolamide, Rivastigmine tartrate, Carbidopa/levodopa, Inflatable abdominal binder, inflatable abdominal binder (sham)
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 85 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children

NCT00178503
Conditions
Autism, Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate-extended release, Methylphenidate-immediate release, Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
7 Years to 12 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Cannabidiol and CES1 Interactions in Healthy Subjects

NCT04603391
Conditions
Drug Interaction
Interventions
dl-Methylphenidate plus Cannabidiol, dl-Methylphenidate plus Cannabidiol Placebo solution
Drug
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Gainesville, Florida
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Long-Duration Stimulant Treatment Study of ADHD in Young Children

NCT00257725
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
B-MPH
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
4 Years to 5 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Conditions
Traumatic Brain Injury
Interventions
methylphenidate, Placebo
Drug
Lead sponsor
Uniformed Services University of the Health Sciences
Federal
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 2 Interventional Results available

Psychopharmacology for Cocaine Dependence - Buspirone

NCT01267292
Conditions
Cocaine Dependence
Interventions
Buspirone, Placebo for Buspirone, Methylphenidate, Placebo for Methylphenidate
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dopaminergic Modulation of Brain Activation Using Simultaneous PET/Pharmacological MRI

NCT03326245
Conditions
Normal Physiology
Interventions
Methylphenidate Pill, Oral Placebo, Intravenous Placebo, Intravenous methylphenidate
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 2 Interventional Results available

Apathy in Dementia Methylphenidate Trial (ADMET)

NCT01117181
Conditions
Apathy, Alzheimer's Disease
Interventions
Methylphenidate, placebo, Psychosocial intervention
Drug · Other
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Baltimore, Maryland • Charleston, South Carolina
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Placebo, Ritalin LA 20 mg, Ritalin LA 30 mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
725 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
21
States / cities
Little Rock, Arkansas • Beverly Hills, California • Spring Valley, California + 16 more
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Ritalin LA (methylphenidate hydrochloride extended release)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
16
States / cities
Little Rock, Arkansas • Beverly Hills, California • Spring Valley, California + 12 more